Giora Davidai, MD

A practicing Pediatric Nephrologist from 1978 to 1993. Dr. Davidai obtained his M.D. degree at the Sackler School of Medicine, University of Tel Aviv, Israel, and completed residency training in Pediatrics at Rothchild Hospital, Haifa, Israel, a fellowship in Nephrology at Rambam Hospital, Haifa, Israel, and a Pediatric Nephrology fellowship at Duke University North Carolina.  He stayed as faculty at Duke and received an adjunct professorship at Bowman Grey Medical School, Winston Salem, North Carolina for a teaching position.  He is an author of numerous peer- reviewed articles and lectured in many conferences.

Since 1990, Dr. Davidai worked in the pharmaceutical industry at all stages of drug development, from molecule to market. He joined the pharmaceutical industry in order to build a new global bone research team in Glaxo Welcome concentrating on Osteoporosis.  After four years in R&D joined the medical department in GW and helped develop Imitrex and Naramig for Migraine Headache and after their launch became the Global Head of Headache Migraine and Epilepsy clinical development until 1998.

Giora served as Executive Director and Head of the Cardiovascular, Metabolic, CNS and Pulmonary departments at Boehringer Ingelheim from 2000 to 2011.  During this time he oversaw the development and launch of Mirapex XR, Micardis, Micardis HCT, Twynsta, Linagliptin, and Pradaxa.  From 2011-2016 he was the head of the Established Products Department in Clinical Development and Medical Affairs in BI.